Company Profile

Thios Pharmaceuticals
Profile last edited on: 5/17/2018      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2001
First Award
2002
Latest Award
2003
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5980 Horton Suite 400
Emeryville, CA 94608
   (510) 420-6700
   N/A
   www.thiospharm.com
Location: Single
Congr. District: 13
County: Alameda

Public Profile

In June 2005 Thios Pharmaceuticals dissolved and went out of business. Thios Pharmaceuticals had been focused on the discovery, development and commercialization of innovative products targeting sulfation pathways, the addition and subtraction of sulfate molecules to important biological glycoproteins. The key components of sulfation pathways are known to be regulators of cellular communication, which can become dysfunctional in specific diseases such as inflammation, cancer and microbial infection. While the kinases, which attach a phosphate group to proteins, have emerged over the last decade as one of the most exciting and proliferative classes of biological targets, sulfation is rapidly emerging as an innovative field that has the potential to define the next decade of drug discovery research.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2003 1 NIH $100,000
Project Title: Inhibitors of sulfate assimilation as new therapy for TB
2002 1 NIH $99,510
Project Title: An L-Selectin Ligand Antibody for Therapy of Asthma

Key People / Management

  Bruce A Hironaka -- President

  Stefan Hemmerich

Company News

There are no news available.